To print: Select File and then Print from your browser's menu

Title: Boosted Interferon Achieves Sustained Virologic Response With Reduced Liver Complications in Patients With HIV/Hepatitis C: Presented at CROI

"Boosted Interferon Achieves Sustained Virologic Response With Reduced Liver Complications in Patients With HIV/Hepatitis C: Presented at CROI"

By Maria Bishop BOSTON, MA -- February 8, 2008 -- Interferon boosted with ribavirin (IFN+RBV) allows patients who are coinfected with HIV and hepatitis C virus (HCV) to achieve a long-term sustained virologic response while reducing liver complications and mortality. These findings were presented here on February 4 at the 15th Conference on Retroviruses and Opportunistic Infections (CROI). Juan Berenguer, MD, Infectious Diseases-HIV Unit, Hospital Gregorio Marañón, Madrid, Spain, led a team of clinical researchers in an analysis of the Grupo de Estudio del SIDA (GESIDA) 3603 Study Cohort. The GESIDA study was established to follow HIV/HCV patients who started therapy with boosted interferon between January 2000 and December 2005. Overall, 711 coinfected patients were analyzed. Most participants had been treated with ribavirin-boosted pegylated interferon (44% with pegylated interferon alfa-2a; 38% with pegylated interferon alfa-2b); 18% had received conventional (non-pegylated) interferon plus ribavirin. All subjects were followed every 6 months after completion of treatment, for a median of 20 months. A Cox regression analysis was adjusted for Center for Disease Control (CDC) clinical category, HCV genotype, and stage of liver fibrosis. Results demonstrated that patients who achieved a sustained virologic response on interferon plus ribavirin had a decreased risk of developing a liver-related event compared with those who did not achieve a sustained virologic response. The rate of liver-related mortality was 0.23 per 100 person-years versus 1.65 per 100 person-years, respectively; rates of liver decompensation were 0.23 versus 4.33, respectively; rates of hepatocarcinoma were 0 versus 0.83, respectively; rates of liver transplantation were 0 versus 1.02, respectively. Rates of overall mortality in the two groups were 0.46 per 100 person-years versus 3.12 per 100 person-years, respectively. HIV-positive patients with chronic HCV experienced a more rapid progression of liver disease in general than did patients with HCV alone. It has been demonstrated that achievement of sustained virologic response, or continued undetectable HCV viral loads 6 months after completing hepatitis C treatment, reduces progression of liver disease. The long-term benefits of treatment response in coinfected individuals remain unknown. The long-term clinical consequences of this trial are significant, the study authors concluded. [[Presentation title: Sustained Virological Response to Interferon Plus Ribavirin Reduces Liver-Related Complications and Mortality in HIV/HCV Co-Infected Patients. Abstract 60]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.